• Tuberculosis and Respiratory Diseases
• /
• 제80권3호
• /
• pp.230-240
• /
• 2017

Chronic obstructive pulmonary disease (COPD) results in high morbidity and mortality among patients both domestically and globally. The Korean clinical practice guideline for COPD was revised in 2014. It was drafted by the members of the Korean Academy of Tuberculosis and Respiratory Diseases, as well as participating members of the Health Insurance Review and Assessment Service, Korean Physicians' Association, and Korea Respiration Trouble Association. This revised guideline covers a wide range of topics, including the epidemiology, diagnosis, assessment, monitoring, management, exacerbation, and comorbidities of COPD in Korea. We drafted a guideline on COPD management by performing systematic reviews on the topic of management with the help of a meta-analysis expert. We expect this guideline will be helpful medical doctors treating patients with respiratory conditions, other health care professionals, and government personnel in South Korea.

• 혜화의학회지
• /
• 제19권2호
• /
• pp.165-171
• /
• 2011

Objectives: This study analyzed the contents of the research papers of Maekmundong-tang (MMDT). This study was conducted to help development of new clinical application and clinical studies for treating COPD with Oriental medicine. Materials and Methods: We inspected 26 theses and scrutinized their classification, objective diseases, study design, participants, methodological quality of clinical trial. Results: The following results were obtained in this study. 1. The studies of MMDT started in 1989 and have continuously increased, but it decreased recently. 2. The studies were mainly focused on experimental models rather than clinical studies. The topics of studies were mainly relaxation of airway contraction and anti-asthmatic effect. 3. MMDT was showed to have effects on chronic cough and asthma in these papers. Conclusion: MMDT is being used in respiratory disease. However, mechanism study should be conducted at experimental study and more clinical studies on the efficacy of MMDT for chronic respiratory disease are needed.

• 대한한방내과학회지
• /
• 제32권2호
• /
• pp.203-216
• /
• 2011

Objectives : This study was conducted to evaluate the protective effects of bee venom on lipopolysaccharide (LPS)-induced chronic obstructive pulmonary disease (COPD). Methods : In this study, LPS was administrated to Balb/c mice to induce a disease that resembles COPD. 2 hr prior to LPS administration, mice were treated with bee venom via an intraperitoneal injection. Total cell number and neutrophils number in bronchoalveolar lavage fluid were counted and pro-inflammatory cytokines were also measured. For histologic analysis, periodic acid Schiff (PAS) and hematoxylin and eosin (H&E) stains were evaluated. Proliferating cell nuclear antigens (PCNA) were also assessed by immunohistochemistry. Results : On 7 days after LPS stimulation, influx of neutrophils significantly decreased in the bee venom group, compared with the COPD group. In addition, TNF-a and IL-6 levels decreased in bee venom group. Histological results also demonstrated the attenuation effect of bee venom on LPS-induced lung inflammation. Conclusions : These data suggest that bee venom has protective effects on LPS-induced lung inflammation. Therefore, bee venom may represent a novel therapeutic agent for lung inflammation and in particular for COPD.

• Tuberculosis and Respiratory Diseases
• /
• 제80권4호
• /
• pp.317-324
• /
• 2017

Small airway disease (SAD) has been recognized for many years as a central feature of chronic obstructive pulmonary disease (COPD). Histopathology studies have shown that the narrowing and destruction of small airways in COPD combined with inflammatory cell infiltration in the submucosa increases the severity of the disease. SAD is present in the early stages of COPD and becomes more widespread over time as the disease progresses to more severe COPD. The development of inhalers containing extra-fine particles allows the small airways to be pharmacologically targeted. Recent clinical trials have shown the efficacy of extra-fine triple therapy that targets the small airways in patients with COPD. This article reviews the importance and treatment of SAD in COPD.

• 한국대기환경학회지
• /
• 제22권5호
• /
• pp.564-573
• /
• 2006

This study was performed to examine the effect of particulate matter less than 10 ${\mu}m$ in diameter($PM_{10}$) on respiratory-related admission in Seoul, 1999. Daily counts of respiratory-related admission were analyzed by generalized additive model with adjustment for effects of air temperature, humidity, and day of the week as confounders in a nonparametric approach. The results follow associations between $PM_{10}$ and asthma, acute upper respiratory disease, acute lower respiratory disease, pneumonia, and chronic respiratory disease. The relative risks were 1.30(95% CI=1.14$\sim$1.50) for pneumonia, 1.18(95% CI=1.01$\sim$1.37) for acute lower respiratory disease in less than 15 years, respectively. The relative risks were 1.85(95% CI=1.22$\sim$2.81) for acute lower respiratory disease, 1.28(95% CI=1.04$\sim$1.57) for asthma, 1.25(95% CI=1.01$\sim$1.54) for pneumonia and 1.19(95% CI=1.01$\sim$1.41) for acute upper respiratory disease in 15 to 64 years, respectively The relative risks were 1.54(95% CI=1.15$\sim$2.08) for asthma, 1.38(95% CI=1.06$\sim$l.80) for chronic respiratory disease in more than 65 years, respectively. The study showed that $PM_{10}$ was considerably affects daily counts of respiratory-related admission in Seoul, 1999 Statistically significant associations were mostly found in the adult group like If to 64 years. The highly relative risks come out in the elderly.

• Tuberculosis and Respiratory Diseases
• /
• 제79권4호
• /
• pp.241-247
• /
• 2016

Bronchodilators are the cornerstone of symptomatic chronic obstructive pulmonary disease (COPD) treatment. They are routinely recommended for symptom reduction, with a preference of long-acting over short-acting drugs. Bronchodilators are classified into two classes based on distinct modes of action, i.e., long-acting antimuscarinics (LAMA, once-daily and twice-daily), and long-acting ${\beta}2$-agonists (LABA, once-daily and twice-daily). In contrast to asthma management, evidence supports the efficacy of both classes of long-acting bronchodilators as monotherapy in preventing COPD exacerbations, with greater efficacy of LAMA drugs versus LABAs. Several novel LAMA/LABA fixed dose combination inhalers are currently approved for COPD maintenance treatment. These agents show superior symptom control to monotherapies, and some of these combinations have also demonstrated superior efficacy in exacerbation prevention versus monotherapies, or combinations of inhaled corticosteroids plus LABA. This review summarizes the current data on clinical effectiveness of bronchodilators alone or in combination to prevent exacerbations of COPD.

• Tuberculosis and Respiratory Diseases
• /
• 제83권3호
• /
• pp.185-194
• /
• 2020

Blood eosinophil counts have emerged as a chronic obstructive pulmonary disease (COPD) biomarker that predict the effects of inhaled corticosteroids (ICS) in clinical practice. Post-hoc and prospective analysis of randomized control trials have shown that higher blood eosinophil counts at the start of the study predict a greater response to ICS. COPD patients with frequent exacerbations (2 or more moderate exacerbations/yr) or a history of hospitalization have a greater response to ICS. Ex-smokers also appear to have a greater ICS response. Blood eosinophil counts can be combined with clinical information such as exacerbation history and smoking status to enable a precision medicine approach to the use of ICS. Higher blood eosinophil counts are associated with increased eosinophilic lung inflammation, and other biological features that may contribute to the increased ICS response observed. Emerging data indicates that lower blood eosinophil counts are associated with an increased risk of bacterial infection, suggesting complex relationships between eosinophils, ICS response, and the airway microbiome.

• Tuberculosis and Respiratory Diseases
• /
• 제79권4호
• /
• pp.307-311
• /
• 2016

Pulmonary strongyloidiasis is an uncommon presentation of Strongyloides infection, usually seen in immunocompromised hosts. The manifestations are similar to that of acute exacerbation of chronic obstructive pulmonary disease (COPD). Therefore, the diagnosis of pulmonary strongyloidiasis could be challenging in a COPD patient, unless a high index of suspicion is maintained. Here, we present a case of Strongyloides hyperinfection in a COPD patient mimicking acute exacerbation, who was on chronic steroid therapy.

• 환경위생공학
• /
• 제8권1호
• /
• pp.93-105
• /
• 1993

The major purpose of this study was to determine the effects of air pollution on respiratory diseases. From the analysis of $SO_2$, $NO_2$ and TSP levels measured at two air pollution monitoring stations(K & E area) of Seoul during Jan. 1988-Dec. 1990, pollution level of K area was higher than E area. Insurance out-patient records for the medical fee reimbusement submitted to the National Federation of Medical Insurance from Jan. to Dec. 1990 were used in order to assess the occurrence of respiratory disease. The results were as follows ; 1. The annual mean levels of $SO_2$, $NO_2$ and TSP in K area were 0.08lppm, O.03lppm and 173.4${\mu}g/m^3$, whereas those of E area were 0.044ppm, 0.02lppm and 146.0 ${\mu}g/m^3$ respectively. The mean levels of above three air pollutants between two areas showed difference about 1.2 times-1.8 times by air pollutant. 2. The monthly out-patient incidence rates of chronic obstructive pulmonary diseases, chronic bronchitis and asthma in K area were higher when compared with those of E area. The monthly out-patient incidence rates of above three chronic respiratory disease of two areas studied showed statistically significant difference about 1.3 times, 2.7 times, 1.4 times respectively. No difference were, however, shown in acute respiratory infections. 3. Highest incidence rates of out-patients could be observed among the group of children less than 10 years old, while adult out-patient incidence rates increased as age increased. 4. The relation between air pollution and chronic respiratory disease was obvious especially, the strongly significant correlation was observed between $NO_2$ and chronic bronchitis.

• 대한한의학회지
• /
• 제40권3호
• /
• pp.87-98
• /
• 2019

Objectives: Patients with respiratory diseases are increasing as air pollution due to fine dust gets worse. Diseases that occupy a large proportion of respiratory diseases in medical institutions are acute bronchitis, chronic bronchitis and Allergic rhinitis. The number of patients with all three diseases is gradually increasing. This study was to suggest assignment of medicine policy for improving accessibility to Korean medical treatment of respiratory diseases analyzing the current treatment status of acute bronchitis, Chronic bronchitis and Allergic rhinitis patients in Western medical and Korean medical institutes in this situation. Methods: This study used 2017 National patient sample data from the Korean Health Insurance Review and Assessment Service for research. Acute bronchitis, Chronic bronchitis, Allergic rhinitis was according to KCD code. This research contains Socio-demographic analysis classified by sex and age, the number of three disease's patients. Also the number of medical treatment, the expense of recuperation cost, medical practices were analyzed compare with Western and Korean medicine. Results: The incidence of three diseases is higher among female than male. There are many patients under the age of 10 in the case of acute bronchitis and allergic rhinitis, while there are many patients over 50 years of age in chronic bronchitis. Western medical treatment take up a larger proportion than Korean medical treatment in part of the number of three disease's patients, the number of medical treatment, the expense of recuperation cost. Conclusions: Much more patients of these diseases visit in Western medical clinic and hospital than Korean medical clinic and hospital for treatment. There are many parts of Korean medical treatment that are not covered by Health insurance benefits like herbal decoction, pharmacopuncture, etc. Korean medicine need to do the efforts for expanding medical field in variety. Also it is demanded for institutional support for reduction of the cost burden and improving on accessibility of Korean medical treatment in order to treat with the increase in respiratory diseases due to fine dust.